non-arteritic ischemic optic neuropathy
Conditions
Sponsors
Chiba university Department of Ophthalmology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Non-arteritic ischemic optic neuropathy patients Age: 50 years of age or older, less than 80 years of age (at the time of obtaining informed consent) Vision: Hand motion or more, and 0.5 of decimal visual acuity or less Patients after receiving a sufficient explanation Upon participation in the present study, after an adequate understanding, the document agreed by the free will of the patient himself was obtained
Exclusion criteria
Exclusion criteria: Arteritic ischemic optic neuropathy patients Patients with vitreous macular traction syndrome, macular edema, macular lesions such as epiretinal mebrane Patients admitted the loss of vision caused by eye diseases other than ischemic optic neuropathy, the study director (sharing) doctor was ineligible Patients retinal vein occlusion, have merged the retinal artery occlusion Patients who are complicated by diabetic retinopathy Patients who are complicated by glaucoma History of optic nerve diseases other than ischemic optic neuropathy Inflammation of the external eye, the merger of the infection or severe dry eye Patients who use oral of Methycobal within 31 days, oral circulatory disorder improving drugs, oral platelet aggregation inhibitor, the drug or the like of oral corticosteroids (eye drops are excluded) Patients who underwent intravenous administration of prostaglandin E formulation within 31 days Patients who underwent a stellate ganglion block within 31 days Patients with unoprostone eye drops within 31 days Patients within three months a history of eye surgery Drug that you plan to use during the test period (ophthalmic anesthetic, mydriatics, etc.) with respect to, history of drug allergy Patients likely to have been pregnant or pregnant. Patients during breast-feeding. Patients who wish to become pregnant during the study period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety (adverse events such as decrease of visual function, skin disorders) Evaluated at the time of 1 hour, 1 week, 2 weeks, and 4 weeks after the end of the treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| 1:visual acuity 2:Retinal sensitivity 3:electroretinogram 4:Optical coherence tomography 5:Visual field 6:Quality of vision 7:Critical fusion frequency | — |
Countries
Japan
Contacts
Public ContactGen Miura
Chiba university Department of Ophthalmology
Outcome results
None listed